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Acute myocarditis is defined as an inflammatory
disease of cardiac muscle that may be identified by
clinical or histopathologic criteria [1], and this disor-
der frequently causes left ventricular (LV) dysfunction.
The clinical manifestations of this disorder vary
greatly from asymptomatic to fulminant fashion, in-
cluding severe cardiogenic shock, fatal arrhythmia,
and acute heart failure [2]. In the setting of fulminant
myocarditis [3], one or more mechanical circulatory
support devices, such as intraaortic balloon pump
(IABP), percutaneous cardiopulmonary support
(PCPS), or an LV assist device in combination with
inotropic agents may serve as a bridge to myocardial
recovery [2]. Here we describe a case of presumed
fulminant cytomegalovirus (CMV) myocarditis in
a patient receiving allogeneic bone marrow transplan-
tation (BMT), which was successfully managed with
antiviral therapy and mechanical circulatory support.Figure 1. Clinical course and change of cytomegalovirus antigenemia
after the onset of presumed fulminant cytomegalovirus myocarditis. Ab-
breviations: PCPS, percutaneous cardiopulmonary support; IABP, intra-
aortic balloon pump; MV, mechanical ventilation; CHDF, continuous
hemodiafiltration; GCV, ganciclovir; EF, ejection fraction; CMVAg, cyto-
megalovirus antigenemia; CK, creatine kinase; BMT, bonemarrow trans-
plantation.A 67-year-old Japanese woman, without previous
significant medical history, underwent BMT for acute
myelogenous leukemia (AML) with myelodysplastic
syndrome (MDS)-related changes from a human leu-
kocyte antigen (HLA)-matched sibling donor. A pre-
transplant echocardiography showed normal LV
function with an ejection fraction (EF) of .60%.
CMV antibodies in both donor and recipient were
seropositive. The conditioning regimen was reduced-
intensity conditioning (RIC) containing fludarabine
(Flu), melphalan (Mel), and total body irradiation
(TBI); graft-versus-host disease (GVHD) prophylaxis
consisted of cyclosporine (CsA) and short-term meth-
otrexate (MTX). Prophylaxis against viral infection
was performed with acyclovir, and CMV pp65 antige-
nemia was monitored weekly as a guide for preemptive
therapy. Engraftment was achieved on day 123 post-
transplantation and complete hematologic and cytoge-
netic remission was confirmed on day 128. As she
developed acute GVHD (aGVHD) grade II with
skin involvement, methylprednisolone (mPSL) was
given from day 149. Five days after the initiation of
mPSL, she suddenly developed generalized seizure,
deterioration of consciousness and high-grade fever,
accompanied by an abrupt drop in blood pressure.
Blood tests showed liver injury with elevation of aspar-
tate amino transferase (348 IU/L), alanine amino
transferase (120 IU/L), and lactate dehydrogenase
(1456 IU/L), as well as cardiac damage such as eleva-
tion of creatine kinase 262 U/L (isoform CK-MB 57
U/L). A chest X-ray demonstrated cardiomegaly, mas-
sive pulmonary congestion, and bilateral pleural effu-
sion. An ECG showed no site-specific ST-segment
alteration, and echocardiography showed markedly
impaired LV function (EF, 16%). Magnetic resonance
imaging (MRI) of the brain showed high-intensity
areas in the bilateral amygdala and pulvinar on the
T1-weighted and fluid attenuated inversion recovery
image, suggesting limbic encephalitis. As coronary an-
giography showed no coronary artery stenosis to ex-
plain the severe impairment of LV systolic function,
fulminant myocarditis complicated with hepatitis and
encephalitis was thus suspected. Because of refractory
cardiogenic shock against medical treatment accompa-
nied with persistent ventricular tachycardia, mechani-
cal cardiopulmonary support in combination with
IABP, PCPS, mechanical ventilation (MV), and con-
tinuous hemodiafiltration had to be initiated for the
patient. The next day, as CMV pp65 antigenemia
was found to be increased (25 positive cells in 2 slides).
As systemic fulminant CMV infection was strongly
suspected, antiviral therapy with ganciclovir at a dose129
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day for 3 days) was started. Blood culture was negative
for any pathogens. Serologic tests for autoimmune
diseases and fungal antigen tests as well as viruses, in-
cluding echovirus, coxsackie virus, and human immu-
nodeficiency virus (HIV), were all negative. Serologic
tests for toxoplasmosis only indicated past infection.
Similarly, quantitative polymerase chain reaction
(PCR) in blood for herpes simplex virus (HSV), vari-
cella-zoster virus (VZV), Epstein-Barr virus (EBV),
adenovirus, human herpes virus 6, parvovirus B19,
and hepatitis B and C virus were all negative. On the
contrary, CMV PCR was strongly positive (7000
copy/mL). Thus, consistent with the result of CMV
pp65 antigenemia, CMV was diagnosed as the main
pathogen of fulminant myocarditis. Because adminis-
tration of ganciclovir was started, her general condi-
tion dramatically improved, CMV antigenemia
decreased to negative value after the transient increase
(peak, 365 positive cells in 2 slides), and all of mechan-
ical cardiopulmonary support devices were success-
fully removed at 2 weeks after their initiation
(Figure 1). Five months after transplantation, she re-
mains in complete remission, without evidence of
heart failure or cardiogenic shock.
CMV infection is a major cause of morbidity and
mortality after hematopoietic stem cell transplantation
(HSCT). Although CMV is a common pathogen of
myocarditis in heart transplant recipients [4], there
were few reports on this disease after allogeneic
HSCT. In this case, she developed presumed fulmi-
nant CMV myocarditis after allogeneic BMT, and
was successfully treated with antiviral therapy and
mechanical circulatory support. Fulminant myocardi-
tis is characterized by an acute onset of severe hemody-
namic instability, and has better long-term prognosis
than patients with nonfulminant myocarditis if recog-
nized promptly and successfully managed with appro-
priate supportive care with inotropes or mechanical
circulatory support [3]. Thus, initiation of mechanical
circulatory support should be useful as a bridge to
recovery for the treatment of fulminant myocarditis
even in allogeneic HSCT recipients. Considering the
efficacy of antiviral therapy, CMV myocarditis should
be taken into account when a patient develops a sudden
onset of acute heart failure or cardiogenic shock after
allogeneic BMT.
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Chromosomally Integrated
Human Herpesvirus 6:
Transmission via Cord Blood-
Derived Unrelated
Hematopoietic Stem Cell
Transplantation
In 1997, Daibata et al. [1] highlighted the remark-
able chromosomal integration of human herpesvirus 6
(HHV6) DNA. We identified a unique case of chro-
mosomally integrated HHV6 (CI-HHV6) after
uncomplicated successful unrelated cord blood stem
cell transplantation (CBT).
A 1.8-year-old boy with mucopolysaccharidosis
type I (Hurler phenotype) was referred for CBT and
received a myeloablative (MA) conditioning regimen
(busulfan [Bu] 480 mg/m2, cyclophosphomide [Cy]
200 mg/kg), including serotherapy with thymoglobu-
lin (Genzyme Corporation, Cambridge, MA). Subse-
quently, a total of 1.5  105 CD341 and 2.5  107
nucleated cells/kg of the recipient bodyweight were in-
fused. As graft-versus-host disease (GVHD) prophy-
laxis, cyclosporine A (CsA; dose is based on plasma
